A new study led by researchers at The University of Texas MD Anderson Cancer Center has discovered that loss of metabolic fitness in chimeric antigen receptor (CAR) natural killer (NK) cells is a critical mechanism of resistance, ...
Jul 26, 2023
0
68
Engineering T cells to destroy cancer cells has shown success in treating some types of cancer, such as leukemia and lymphoma. However, it hasn't worked as well for solid tumors.
Jul 5, 2023
0
49
Three young patients with relapsed T-cell leukemia have now been treated with base-edited T-cells, as part of a "bench-to-bedside" collaboration between University College London (UCL) and Great Ormond Street Hospital for ...
Jun 14, 2023
0
50
Patients with early relapsed or refractory large B-cell lymphoma had significantly improved overall survival when treated with the chimeric antigen receptor (CAR) T cell therapy axicabtagene ciloleucel (axi-cel) when compared ...
Jun 5, 2023
0
33
In the five years since the FDA's initial approval of chimeric antigen receptor (CAR) T cell therapy, Penn Medicine has gleaned 20 additional approvals related to drugs and techniques to treat or detect cancer.
May 29, 2023
0
33
Prostate cancer frequently metastasizes to the bone and is incurable. Moffitt Cancer Center researchers are working to identify new treatment options for this subset of patients. In a new article published today in Science ...
May 3, 2023
0
33
Peter Mac researchers have developed a new approach to chimeric antigen receptor (CAR) T-cell therapy which has proven effective in fighting solid cancer tumors.
Apr 7, 2023
0
94
A therapy that bolsters the immune system may not only help certain cancer patients live longer, but better, a new study finds.
Apr 5, 2023
0
21
Custom-made to attack cancer cells, CAR T-cell therapies have opened a new era in the treatment of human cancers, particularly, in hematologic malignancies. All too often, however, they display a frustrating trait inherited ...
Mar 20, 2023
0
162
Although chimeric antigen receptor (CAR) T cell therapy has shown potential in the treatment of hematological malignancies, its application in solid tumors is unsatisfactory due to the harsh physical barriers and immunosuppressive ...
Mar 15, 2023
0
79
